RAB7A

Across TCGA pan-cancer cohorts, RAB7A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RAB7A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RAB7A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RAB7A is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where RAB7A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAB7A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.424	<.001	11	view →
COAD	Female	III,IV	+0.245	<.001	11	view →
LSCC	Male	III,IV	+0.385	<.001	8	view →
OV	All	All	+0.403	.006	2	view →
PDAC	Female	II,III,IV	+0.187	.026	2	view →
CCRCC	Male	All	−0.084	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RAB7A–HNSC

Open the HNSC breakdown →